Los Altos Hills, California. October 2021.
I didn’t get invited to this party. Nobody does — unless someone decides you belong there.
The house sits above the fog line, perched in the hills above Palo Alto, behind a gate that doesn’t appear on any map.
The kind of property that tells you, before you’ve stepped inside, that the man who owns it has already won at the game most people are still playing.
The host: Yuri Milner. Russian-born billionaire.
Physics dropout turned tech investor. The man who wrote a $200 million check to Facebook when Mark Zuckerberg was still being dismissed as a college kid.
Net worth: north of $5 billion. A private jet. The Breakthrough Prizes — his personal $3 million annual awards for scientists, the Nobel Prize of Silicon Valley, handed out at a black-tie ceremony in a NASA hangar.
Milner is the kind of person who, when he decides something matters, tends to be right about it five years before anyone else.
He’s tested for COVID-19 at the gate — this is still 2021. Inside, forty people take their seats in a private theater built into the property. Scientists, mostly. A few investors. No press. No social media. The kind of gathering where ideas are shared because everyone in the room has signed, implicitly, a covenant of seriousness.
What Milner has assembled on this October afternoon is not a tech conference. It is not a wellness retreat. It is not a panel on AI or climate or geopolitics.
It is a two-day scientific summit on how to stop human beings from dying.
One by one, researchers take the stage. They show footage: old mice, arthritic, barely able to drag themselves across their cage floors, who have been surgically joined to young mice so their circulatory systems intermingle. Within weeks — weeks — the old mice are transformed. Stronger. Faster. Their organs regenerating. Their brains functioning at levels years younger than their chronological age.
Then come the results on cellular reprogramming. On senolytic drugs. On epigenetic clocks that can measure — with stunning accuracy — not how old you are, but how fast you are aging.
The cumulative message of two days of presentations lands like a verdict: aging is not a law of nature. It is a biological process. And biological processes can be interrupted, slowed, and — in some cases — reversed.
Milner walks away from that weekend with a conviction so strong that within months, he and Jeff Bezos are quietly writing checks to a new company that doesn’t yet have a name. That company — Altos Labs — launches publicly in January 2022 with a funding round of $3 billion.
The largest single raise in the history of biotechnology.
Not for a drug. Not for a vaccine. Not for a new indication on an existing molecule.
For the reversal of human aging itself.
I want to tell you what happened next. Because what happened after that party in the hills — the capital that followed, the science that accelerated, the public market opportunity that is now sitting, mispriced and overlooked, in plain sight — is the reason I’ve spent the last four months building the most comprehensive investment playbook I’ve ever written.
There’s a question nobody in finance wants to ask
Before I show you the numbers, I want to ask you something uncomfortable.
Are you going to die?
Obviously. We all know the answer. So we bury it. We build elaborate structures around it — religious, philosophical, cultural — to make the fact of our own disappearance bearable. For ten thousand years, every civilization that has ever existed has produced some version of the same consoling fiction: you won’t really vanish. You’ll continue, somewhere else, in some other form.
Those fictions worked for a long time.
They are working less and less.
For the first time in recorded history, the majority of adults in developed nations describe themselves as non-religious or unaffiliated. The psychological safety net that organized religion provided — the promise that death is not the end — is fraying. And behind it, unchanged, is what was always there: the raw, biological terror of non-existence.
This is not a philosophical observation. It is an economic one.
Because when the most rational, data-driven, atheist-leaning cohort of capital allocators on earth — the people who built Google, Amazon, PayPal, and OpenAI — confronts death without the comfort of religion, they do the only thing that makes sense to them.
They fund the science that might solve it.
And the money they are deploying — right now, quietly, at a scale the financial press has barely begun to cover — is the most important investment signal I’ve seen in fifteen years.
$314 billion. That’s where this market is headed by 2030, according to Deloitte’s analysis. Growing at 25.2% per year. Faster than AI software. Faster than electric vehicles. Faster than genomics.
And public equity markets have barely noticed.
That is the trade.
The arms race nobody’s covering
Let me show you what the smart money is actually doing.
Jeff Bezos — $3 billion into Altos Labs (cellular reprogramming). Also backed Unity Biotechnology, which develops senolytic drugs that selectively destroy aging cells. His final letter to Amazon shareholders, written before he stepped down as CEO, quoted the biologist Richard Dawkins at length: “Staving off death is a thing that you have to work at… if living things didn’t work actively to prevent it, they would eventually merge into their surroundings, and cease to exist.”He wasn’t talking about Amazon. He was telling you where he was going next.
Sam Altman — $180 million of his own money into Retro Biosciences. The entire seed round. By himself. His stated mission: add 10 years to the average human lifespan. As of January 2025, Retro is raising a $1 billion Series A at a $5 billion valuation. One slide from their internal fundraising deck reads: “Longevity will be the greatest pharma market of all time.”
Larry Ellison — Oracle’s co-founder has donated over $430 million to aging research across his foundation’s fifteen-year run. His biographer once asked him why death consumed so much of his attention. Ellison’s answer: “Death has never made any sense to me. How can a person be there and then just vanish, just not be there?” That question has now cost him nearly half a billion dollars in research grants.
Larry Page — Google’s co-founder launched Calico (California Life Company) in 2013 — a secretive anti-aging research lab backed with up to $750 million from Alphabet. Calico and AbbVie have since each committed $1.75 billion to a joint drug discovery effort. That’s $3.5 billion in combined committed capital from one partnership alone.
Peter Thiel — More than $7 million to the Methuselah Foundation. Breakout Labs, his early-stage biotech fund, with a mandate to “de-risk” the most radical scientific ideas. And a very public interest in parabiosis — the science of biological rejuvenation through blood factors — years before anyone else in finance was willing to say the words out loud.
You are looking at a coalition of the most consistently prescient capital allocators of the last thirty years. The people who were right about search, right about social, right about payments, right about AI.
They are not doing this for publicity. They are not doing this for philanthropy. They are doing this because they have run the numbers, assessed the science, and concluded that the reversal of aging is a solvable engineering problem — and that the people who fund the solution early will capture a historically disproportionate share of the value created.
The man who sold his company to PayPal and started aging backwards
Bryan Johnson is 47 years old. In 2013, he sold his payment processing company Braintree — which also owned Venmo — to PayPal for $800 million.
Most founders at that point buy a boat. Travel. Start a foundation. Put their name on a hospital wing.
Johnson hired 30 doctors.
His protocol — Project Blueprint — is the most extreme, most rigorous, most publicly documented anti-aging experiment ever conducted on a living human being. He spends $2 million per year on it. Every biomarker measured. Every intervention tracked. Every result published, in full, for the world to scrutinize.
The results, as of early 2026:
Epigenetic aging pace of 0.66 years per chronological year — he is aging roughly one-third slower than a typical 47-year-old
Skin biological age: reduced from a measured 64 to 36 — a 28-year reversal
Telomere length extended by 2.6%, reaching baseline levels comparable to a 10-year-old’s
Inflammatory marker hsCRP: below detectable levels — effectively zero systemic inflammation
Telomerase activity: equivalent to a 12-year-old
Netflix made a documentary about him. It’s called Don’t Die: The Man Who Wants to Live Forever.
When I watched it, I expected a wealthy eccentric with too much money and not enough humility. What I found was something more unsettling: a rigorous, data-obsessed argument that the tools to measure and manipulate biological aging exist today, right now, and are producing results that cannot easily be dismissed.
You don’t have to believe Johnson is going to live forever to find his project investable.
You only have to believe that what he’s doing is early evidence of a technology curve — the same way the first personal computers were slow, expensive, and impractical, and the only people who cared were obsessives with too much time and money. Until suddenly everyone cared.
What the science actually says (and why your portfolio should care)
For most of human history, aging was treated as physics, not biology. An inevitability, not a process.
That consensus has collapsed.
Scientists now understand aging as the accumulation of damage across nine distinct biological mechanisms — the “hallmarks of aging”: genomic instability, telomere shortening, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.
Nine mechanisms. Each measurable. Each, in principle, targetable with drugs.
The most commercially advanced of these is cellular senescence — the buildup of what researchers call “zombie cells” in the body. These are cells that have stopped dividing but refuse to die.
Instead, they sit in tissue and secrete a cocktail of inflammatory signals that actively poison surrounding cells. Senescent cells accumulate with age and are now understood to be a primary driver of arthritis, Alzheimer’s, cardiovascular disease, type 2 diabetes, and multiple cancers — simultaneously.
Drugs called senolytics, which selectively eliminate these zombie cells, have extended healthy lifespan by 25 to 36% in animal studies. Unity Biotechnology, backed by both Bezos and Thiel, is the furthest along in human trials. Early data on vision, mobility, and cognition is encouraging.
Here is the regulatory detail that most investors miss: the FDA does not currently recognize aging as a disease — which has blocked the entire field from standard drug approval pathways.
But the TAME trial (Targeting Aging with Metformin), backed by the National Institute on Aging, is the first clinical study designed explicitly to demonstrate that a drug can target aging itself.
If TAME succeeds, it creates a regulatory category that doesn’t currently exist — and opens the floodgates to an entirely new class of drug approvals.
We are not there yet. But the direction is unmistakable. And the investors who wait for confirmation before entering will pay a very different price than those who are already positioned.
Why the market is mispricing this — and what happened last time
I want to make a historical argument. Sixty seconds. Stay with me.
In 1990, the Human Genome Project launched. It was a government science project. Pharmaceutical executives publicly mocked the idea that sequencing DNA would produce commercial drugs within their lifetimes.
Genomics was, to mainstream investors, an academic curiosity funded by NIH grant money.
Then the sequence was published. The tools got cheap. Illumina built the sequencer that made it economical for anyone. And then a generation of companies — Moderna, BioNTech, CRISPR Therapeutics, Regeneron — built on that foundation and created hundreds of billions in market value in less than twenty years.
The longevity sector is at the same inflection point genomics was at in approximately 2005. The science has crossed a threshold. The capital has arrived.
The regulatory pathway is under construction. And the demographic tailwind is inexorable: by 2035, adults over 65 will outnumber children under 18 in the United States for the first time in history.
Healthcare spending for Americans over 65 currently averages $22,356 per person per year — versus $4,217 for children. That gap is the single most predictable driver of healthcare market growth for the next two decades.
$65 billion in total longevity market revenue in 2023. $314 billion projected by 2030. CAGR of 25.2%.
Venture capital investment in longevity startups more than doubled in 2024, to over $8 billion. Big pharma — AbbVie, Novartis, Eli Lilly — is moving in through licensing deals and partnerships. BioAge Labs and Jupiter Neurosciences both completed IPOs in 2024. Specialized longevity investment funds nearly doubled their membership last year.
The floodgates have not opened. We are at the trickle. And that trickle is where the returns are made.
The Elon Musk problem — and what it actually tells us
Elon Musk has a public position on longevity research. He stated it plainly: “I don’t think we should try to have people live for a really long time. It would cause asphyxiation of society because the truth is, most people don’t change their mind. They just die. So if they don’t die, we will be stuck with old ideas.”
Here is what I want to say about this, as clearly as I can: Musk is right.
On the philosophical merits, his argument is sound.
Thomas Kuhn made the same point in The Structure of Scientific Revolutions — paradigms don’t shift when new evidence arrives.
They shift when the generation defending the old paradigm dies and is replaced. Death is, in a real sense, the engine of human intellectual renewal.
So yes. Elon Musk is correct.
And it doesn’t matter at all.
Here’s why.
The fear of death is the oldest and most powerful motivating force in human history. The pyramids were built to defeat death. The cathedrals of Europe were raised to defeat death. Medicine, surgery, antibiotics, vaccines — the entire arc of modern science is, at its core, a species-wide campaign against mortality.
In 1900, global average life expectancy was 31 years. Today it is 73.
We have already more than doubled human lifespan in a single century. Nobody voted on it. Nobody asked whether it was philosophically optimal. The demand was so overwhelming that it simply happened.
But here is what’s different now — and what makes this moment genuinely unprecedented as an investment thesis.
For most of that campaign against death, organized religion served as a pressure valve. The promise of an afterlife gave people a way to make peace with mortality that didn’t require biological solutions.
You didn’t need a senolytic drug if you believed in heaven. The fear existed; the religion absorbed it.
That absorption mechanism is failing. In the United States, the UK, France, Germany, Japan — across every developed market — secularization is accelerating. The cohort of people who believe in a literal afterlife is shrinking with every generation. And the fear doesn’t disappear when the religion does. It simply loses its outlet.
What you are watching, in the billions flowing into Altos Labs and Retro Biosciences and the longevity clinics opening in every major city, is that fear finding a new channel. Not prayer. Science.
Musk is right that extending lifespans indefinitely might be bad for society. But he is expressing a personal philosophical preference in a world where billions of people — including the five wealthiest investors in Silicon Valley — have already decided they don’t share it.
My job as an investor is not to have opinions about what should happen.
My job is to identify what will happen, based on where capital and human motivation are pointing. And both are pointing, with increasing force, toward longevity.
One more thing Musk gets wrong: the framing. The most serious researchers in this field — the Altos Labs scientists, the TAME trial investigators, Bryan Johnson’s team — are not trying to make people immortal.
They are trying to eliminate the last ten years of human life as most people currently experience them: the decade of decline. The Alzheimer’s. The hip fractures. The loss of independence. The years in a nursing home that nobody chose and nobody wanted.
If you frame the longevity thesis as “living to 150,” Musk’s philosophical objection has some force. If you frame it as “eliminating the decade of medical dependency that currently costs families and governments trillions of dollars” — which is the actual near-term commercial opportunity — his objection dissolves entirely.
This is the playbook. Not immortality. Compression of morbidity. Fewer bad years. More productive ones.
That is a market worth $314 billion by 2030. And it has barely been touched by public market investors.
What I built — and what’s behind the paywall
I have spent four months doing what I do whenever I find a structural theme that the market hasn’t priced: going all the way in.
Sixty-plus earnings transcripts. Regulatory pipeline mapping across the FDA, EMA, Japan’s PMDA, and South Korea’s MFDS.
Conversations with analysts who cover aging biotech in Boston, London, and Tokyo. Financial modeling across twelve public companies in three sub-sectors.
What I built is not a listicle. It’s not five tickers with a paragraph each. It’s a complete economic map of the longevity sector — who’s building what, who supplies whom, where the real barriers to entry are, and how the capital flows are going to move over the next five years.
Here’s exactly what premium subscribers get:
🎯 My full longevity portfolio — every position, fully disclosed
Twelve public companies across three distinct investment approaches: pure-play longevity biotechs, enabling technology platforms (the companies building the tools the biotechs depend on), and consumer longevity infrastructure plays that don’t require any single drug to succeed. For each position: ticker, entry price, 24-month target, position size as a percentage of portfolio, and the one-sentence thesis. Including one position I’m currently sizing up aggressively — and one I’m short.
📊 The 5 sub-sectors, ranked by risk-adjusted return potential
Senolytics. Epigenetic reprogramming. Longevity diagnostics. AI-driven drug discovery. Consumer longevity platforms. I rank them by where the margins are expanding fastest, where the regulatory risk is most manageable, and where the market is mispricing most aggressively. The sub-sector most investors find exciting is the one I’m most cautious on. I’ll explain exactly why.
🔬 How to win without picking the right drug
The history of biotech investing is brutal. Every year, investors pick the right thesis and the wrong company. In the longevity sector, where binary clinical trial outcomes can destroy 70% of a stock’s value overnight, picking individual drug companies is not how I’m primarily playing this. I’ll show you the “picks-and-shovels” approach — the companies that supply reagents, instruments, computational platforms, and biological samples to every longevity lab on earth, regardless of which molecule ultimately works. These are my highest-conviction, lowest-binary-risk positions.
🧬 The 3 catalysts I’m positioning around in 2026 and 2027
TAME trial results. Altos Labs’ first human safety data. An FDA guidance document that could redefine aging as a treatable condition. For each: the companies best positioned, the expected timeline, and how to build position 60 to 90 days ahead of the announcement. This calendar alone is worth the subscription.
📉 The sectors that longevity will destroy — and how to short them
This is the section nobody else is writing. If healthspan extends by a decade — if the years of medical dependency that currently drive the economics of nursing homes, long-term care insurance, and certain chronic disease drug categories are compressed or eliminated — entire industries face structural disruption.
I identify the three sectors most exposed to this compression, the specific companies within them carrying the most risk, and how I’m positioning short exposure as a hedge and a return driver. Bryan Johnson has articulated an economic vision for what the longevity economy displaces that is more interesting than almost anything I’ve read in mainstream financial media. I’ll walk through that thesis in detail.
🌏 Where the real alpha is hiding — Japan, South Korea, and the undervalued Asian longevity trade
Japan has the oldest population of any major economy on earth. South Korea has the lowest birth rate. Both governments are funding longevity research at a scale that dwarfs their relative coverage in Western financial media. I identify specific companies in both markets trading at significant discounts to their US equivalents — with comparable or superior science — that most American investors have never heard of.
⚠️ The 3 scenarios that kill this thesis — and how I’m hedged against each
A catastrophic TAME trial failure. An FDA reversal on the regulatory pathway. A systemic biotech bear market. I’m not a permabull. I show you exactly what would invalidate this playbook, the specific signals I’m watching, and the two inverse positions I’m holding as insurance.
🧮 Risk management in a binary-outcome sector
How to size positions when individual stocks can lose 70% on a single readout. Why I cap any single longevity position at 6% of total portfolio. The one exception I’m currently making. My stop-loss rules. And the framework I use to distinguish between a thesis being wrong and a stock being volatile — the most important distinction in biotech investing.
The first company I profile in the playbook is not a biotech company.
It is a data and diagnostics platform that has quietly become the operating infrastructure of longevity research globally — used by Altos Labs, multiple NIH-funded programs, and clinical longevity practices across the US, UK, and Japan. It generates recurring revenue from biological age testing for hundreds of thousands of individuals, and its model is structurally more like a SaaS business than a pharma company.
It is trading at a fraction of the multiple its revenue growth would command in any comparable software-adjacent vertical. It is, in my view, the single best risk-adjusted entry point into the longevity supercycle available in public markets today. And it is flying almost entirely under institutional radar.
You will understand within ten minutes of reading the playbook why it is my anchor position — and why I think it deserves to be yours too.